-
May 30, 2024 | 
medscape.com | Fatima Cardoso |Priscilla K Brastianos |Laura A. Huppert |Orit Kaidar-Person
Authors and Disclosures Fatima Cardoso, MD Director, Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal Disclosure: Fatima Cardoso, MD, has disclosed the following relevant financial relationships: Personal financial interest in form of consultancy role for: Amgen; Astellas/Medivation; AstraZeneca; Celgene; Daiichi-Sankyo; Eisai; GE Oncology; Genentech; Gilead; GlaxoSmithKline; IQVIA; Macrogenics; Medscape; Merck-Sharp; Merus BV; Mylan; Mundipharma; Novartis; Pfizer; Pierre-Fabre;...
-
May 17, 2024 | 
acsjournals.onlinelibrary.wiley.com | Annie L. Hsieh |Wenya Linda Bi |Vijaya Ramesh |Priscilla K Brastianos
Priscilla K.
-
Feb 1, 2024 | 
thejns.org | Hugues Duffau |Mitchel Berger |Priscilla K Brastianos |Nader Sanai
Correspondence Hugues Duffau: [email protected]. INCLUDE WHEN CITING DOI: 10.3171/2023.11.FOCUS23731.
-
Oct 26, 2023 | 
healio.com | Drew Amorosi |Mindy Valcarcel |Priscilla K Brastianos |Carey Anders
You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An estimated 10% to 40% of patients with solid tumors develop brain metastases.
-
Aug 1, 2023 | 
thejns.org | Manish K. Aghi |Priscilla K Brastianos |Albert Kim |Steven Kalkanis
INTRODUCTIONBrain metastases (BMs), the most common adult intracranial tumor,1 confer a worse prognosis than cancers lacking BMs.2 In this issue of Neurosurgical Focus, we integrate information on advancements in BM management, research that will drive future treatments, and a roadmap for future research.
-
Jul 11, 2023 | 
pubmed.ncbi.nlm.nih.gov | Husain Danish |Priscilla K Brastianos
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
-
Jun 2, 2023 | 
nature.com | Priscilla K Brastianos |Anita Giobbie-Hurder |Beth Overmoyer |Sara M. Tolaney |Erica L. Mayer
AbstractBrain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.
-
Apr 21, 2023 | 
nature.com | Maximilian J. Mair |Emilie Le Rhun |Priscilla K Brastianos |Javier Cortés |Hui K. Gan |Michael Weller
Cite this articleMair, M.J., Bartsch, R., Le Rhun, E. et al. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol (2023). https://doi.org/10.1038/s41571-023-00756-zDownload citationAccepted: 21 March 2023Published: 21 April 2023DOI: https://doi.org/10.1038/s41571-023-00756-zShare this articleAnyone you share the following link with will be able to read this content:Sorry, a shareable link is not currently available for this article.
-
Apr 11, 2023 | 
onclive.com | Priscilla K Brastianos
Meningiomas are the most common type of brain cancer—the American Society of Clinical Oncology estimates that the disease represents approximately 40% of primary brain tumors and will affect 42,260 people in the United States in 2023. Priscilla K. Brastianos, MD, an associate professor of medicine with Harvard Medical School and a physician-scientist at Massachusetts General Hospital Cancer Center, investigates the genomic drivers of human brain tumors.
-
Apr 4, 2023 | 
onclive.com | Priscilla K Brastianos
Priscilla K. Brastianos, MD, an associate professor of medicine with Harvard Medical School and a physician-scientist at Massachusetts General Hospital Cancer Center, investigates the genomic drivers of brain tumors. She says there is a clear unmet need for systemic treatment options for aggressive, high-grade meningiomas. Approximately 80% of meningiomas are grade 1 or benign. Many of those are small, asymptomatic, and indolent, and may not require immediate treatment.
